Short Bowel Syndrome

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

LEP, LEPR, INSR, GCG, GLP1R, EHMT1, NOD2, ZGLP1, GH1, EGF, HSPA4, CYLD, ODC1, SLC15A1, GLP2R, SPINK4, SLFN12, SLC26A3, DPP4, PTPN5, CTNNB1

Drugs

Apraglutide, Heparin-binding epidermal growth factor-like growth factor (HB-EGF), amino acids 74-148, Human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment

Apraglutide, Heparin-binding epidermal growth factor-like growth factor (HB-EGF), amino acids 74-148, Human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment, Insulin human, L-Glutamine ( ENDARI, NUTRESTORE ), Oxalobacter formigenes strain HC-1, Teduglutide ( GATTEX, REVESTIVE )

Interested in hearing about new therapies?

Short bowel syndrome is an intestinal failure due to either a congenital defect, intestinal infarction or extensive surgical resection of the intestinal tract that results in a functional small intestine of less than 200cm in length and is characterized by diarrhea, nutrient malabsoption, bowel dilation and dysmobility.